Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

NCT ID: NCT00441727

Last Updated: 2012-07-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2426 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the effect of esomeprazole 20 or 40 mg once daily versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low-dose acetylsalicylic acid.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Ulcer Duodenal Ulcer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Peptic ulcer low-dose ASA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Esomeprazole 40 mg

Esomeprazole 40 mg

Group Type EXPERIMENTAL

Esomeprazole 40 mg

Intervention Type DRUG

Esomeprazole 40 mg once daily

Esomeprazole 20 mg

Esomeprazole 20 mg

Group Type EXPERIMENTAL

Esomeprazole 20 mg

Intervention Type DRUG

Esomeprazole 20 mg once daily

Placebo

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esomeprazole 40 mg

Esomeprazole 40 mg once daily

Intervention Type DRUG

Esomeprazole 20 mg

Esomeprazole 20 mg once daily

Intervention Type DRUG

Placebo

Placebo once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Daily intake of low-dose Aspirin (ASA) - The subject must fulfill at least one of the following (a-e):
* Aged ≥65 years.
* Aged ≥18 years and with a documented history of uncomplicated peptic ulcer(s).
* Aged ≥60 years and naïve to low-dose ASA (ie, treatment started within 1 month prior to randomization).
* Aged ≥60 years and with stable coronary artery disease.
* Aged ≥60 years and with complaints of upper gastrointestinal (GI) symptoms that, as judged by the investigator, requires an Esophagogastroduodenoscopy (EGD) and with the finding of ≥5 gastric and/or duodenal erosions at the baseline endoscopy.

Exclusion Criteria

* Peptic ulcer(s) at baseline esophagogastroduodenoscopy (EGD).
* Reflux esophagitis Los Angeles (LA) classification grade C or D at baseline
* History of peptic ulcer complications such as clinically significant bleeding and/or perforation.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tore Lind, MD, PhD

Role: STUDY_DIRECTOR

AstraZeneca

James Scheiman, MD

Role: PRINCIPAL_INVESTIGATOR

University of Michigan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Birmingham, Alabama, United States

Site Status

Research Site

Tucson, Arizona, United States

Site Status

Research Site

Anaheim, California, United States

Site Status

Research Site

Lancaster, California, United States

Site Status

Research Site

Los Angeles, California, United States

Site Status

Research Site

Orange, California, United States

Site Status

Research Site

San Carlos, California, United States

Site Status

Research Site

San Diego, California, United States

Site Status

Research Site

Torrington, Connecticut, United States

Site Status

Research Site

Boynton Beach, Florida, United States

Site Status

Research Site

Hollywood, Florida, United States

Site Status

Research Site

Jacksonville, Florida, United States

Site Status

Research Site

Jupiter, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

New Smyrna Beach, Florida, United States

Site Status

Research Site

Pembroke Pines, Florida, United States

Site Status

Research Site

Plantation, Florida, United States

Site Status

Research Site

South Miami, Florida, United States

Site Status

Research Site

Tampa, Florida, United States

Site Status

Research Site

Zephyrhills, Florida, United States

Site Status

Research Site

Fulton, Illinois, United States

Site Status

Research Site

Wichita, Kansas, United States

Site Status

Research Site

Shreveport, Louisiana, United States

Site Status

Research Site

Baltimore, Maryland, United States

Site Status

Research Site

Hollywood, Maryland, United States

Site Status

Research Site

Prince Frederick, Maryland, United States

Site Status

Research Site

Brockton, Massachusetts, United States

Site Status

Research Site

Jackson, Mississippi, United States

Site Status

Research Site

Las Vegas, Nevada, United States

Site Status

Research Site

Egg Harbor, New Jersey, United States

Site Status

Research Site

Albuquerque, New Mexico, United States

Site Status

Research Site

Great Neck, New York, United States

Site Status

Research Site

Fayetteville, North Carolina, United States

Site Status

Research Site

Greensboro, North Carolina, United States

Site Status

Research Site

Jacksonville, North Carolina, United States

Site Status

Research Site

Winston-Salem, North Carolina, United States

Site Status

Research Site

Centerville, Ohio, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Dayton, Ohio, United States

Site Status

Research Site

Guthrie, Oklahoma, United States

Site Status

Research Site

Oklahoma City, Oklahoma, United States

Site Status

Research Site

Harrisburg, Pennsylvania, United States

Site Status

Research Site

Cranston, Rhode Island, United States

Site Status

Research Site

Johnston, Rhode Island, United States

Site Status

Research Site

Anderson, South Carolina, United States

Site Status

Research Site

Simpsonville, South Carolina, United States

Site Status

Research Site

Knoxville, Tennessee, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

Ogden, Utah, United States

Site Status

Research Site

Burke, Virginia, United States

Site Status

Research Site

Chesapeake, Virginia, United States

Site Status

Research Site

Christiansburg, Virginia, United States

Site Status

Research Site

Norfolk, Virginia, United States

Site Status

Research Site

Richmond, Virginia, United States

Site Status

Research Site

Milwaukee, Wisconsin, United States

Site Status

Research Site

Capital Federal, Buenos Aires, Argentina

Site Status

Research Site

Loma Hermosa, Buenos Aires, Argentina

Site Status

Research Site

Lomas de Zamora, Buenos Aires, Argentina

Site Status

Research Site

Buenos Aires, Buenos Aires- Argentina, Argentina

Site Status

Research Site

Rosario, Santa Fe Province, Argentina

Site Status

Research Site

Mendoza, , Argentina

Site Status

Research Site

Rosario, , Argentina

Site Status

Research Site

Caboolture, Queensland, Australia

Site Status

Research Site

Carina Heights, Queensland, Australia

Site Status

Research Site

Adelaide, South Australia, Australia

Site Status

Research Site

Ballarat, Victoria, Australia

Site Status

Research Site

Box Hill, Victoria, Australia

Site Status

Research Site

Geelong, Victoria, Australia

Site Status

Research Site

NSW, , Australia

Site Status

Research Site

Chirpan, , Bulgaria

Site Status

Research Site

Pleven, , Bulgaria

Site Status

Research Site

Rousse, , Bulgaria

Site Status

Research Site

Sofia, , Bulgaria

Site Status

Research Site

Varna, , Bulgaria

Site Status

Research Site

Calgary, Alberta, Canada

Site Status

Research Site

Edmonton, Alberta, Canada

Site Status

Research Site

Bay Roberts, Newfoundland and Labrador, Canada

Site Status

Research Site

Carbonear, Newfoundland and Labrador, Canada

Site Status

Research Site

Mount Pearl, Newfoundland and Labrador, Canada

Site Status

Research Site

St. John's, Newfoundland and Labrador, Canada

Site Status

Research Site

Brampton, Ontario, Canada

Site Status

Research Site

Cambridge, Ontario, Canada

Site Status

Research Site

Hamilton, Ontario, Canada

Site Status

Research Site

Niagara Falls, Ontario, Canada

Site Status

Research Site

North York, Ontario, Canada

Site Status

Research Site

Tillsonburg, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Pointe-Claire, Quebec, Canada

Site Status

Research Site

Laval, , Canada

Site Status

Research Site

Longueuil, , Canada

Site Status

Research Site

Québec, , Canada

Site Status

Research Site

Beroun, , Czechia

Site Status

Research Site

Brno, , Czechia

Site Status

Research Site

Liberec, , Czechia

Site Status

Research Site

Litoměřice, , Czechia

Site Status

Research Site

Ostrava - Trebovice, , Czechia

Site Status

Research Site

Podbořany, , Czechia

Site Status

Research Site

Poobram, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Praha 4 - Sporilov, , Czechia

Site Status

Research Site

Tábor, , Czechia

Site Status

Research Site

Jakobstad, , Finland

Site Status

Research Site

Joensuu, , Finland

Site Status

Research Site

Mikkeli, , Finland

Site Status

Research Site

Tampere, , Finland

Site Status

Research Site

Turku, , Finland

Site Status

Research Site

Vantaa, , Finland

Site Status

Research Site

Bochum, , Germany

Site Status

Research Site

Dresden, , Germany

Site Status

Research Site

Ludwigshafen, , Germany

Site Status

Research Site

Lüdenscheid, , Germany

Site Status

Research Site

Magdeburg, , Germany

Site Status

Research Site

München, , Germany

Site Status

Research Site

Oelde, , Germany

Site Status

Research Site

Potsdam, , Germany

Site Status

Research Site

Rodgau-dudenhofen, , Germany

Site Status

Research Site

Siegen, , Germany

Site Status

Research Site

Wangen, , Germany

Site Status

Research Site

Wolmirstedt, , Germany

Site Status

Research Site

Jakarta, , Indonesia

Site Status

Research Site

Semarang, , Indonesia

Site Status

Research Site

Surabaya, , Indonesia

Site Status

Research Site

Yogyakarta, , Indonesia

Site Status

Research Site

México, D.f., Mexico

Site Status

Research Site

Guadalajara, Jalisco, Mexico

Site Status

Research Site

Zapopan, Jalisco, Mexico

Site Status

Research Site

D.F, , Mexico

Site Status

Research Site

Mexico City, , Mexico

Site Status

Research Site

Asker, , Norway

Site Status

Research Site

Bergen, , Norway

Site Status

Research Site

Elverum, , Norway

Site Status

Research Site

Gjøvik, , Norway

Site Status

Research Site

Hamar, , Norway

Site Status

Research Site

Levanger, , Norway

Site Status

Research Site

Lysaker, , Norway

Site Status

Research Site

Oslo, , Norway

Site Status

Research Site

Osteros, , Norway

Site Status

Research Site

Paradis, , Norway

Site Status

Research Site

Stavanger, , Norway

Site Status

Research Site

Tromsø, , Norway

Site Status

Research Site

Ølesund, , Norway

Site Status

Research Site

Manila, , Philippines

Site Status

Research Site

Quezon City, , Philippines

Site Status

Research Site

Bydgoszcz, , Poland

Site Status

Research Site

Chojnice, , Poland

Site Status

Research Site

Chrzanów, , Poland

Site Status

Research Site

Czechowice-Dziedzice, , Poland

Site Status

Research Site

Częstochowa, , Poland

Site Status

Research Site

Elblog, , Poland

Site Status

Research Site

Gdansk, , Poland

Site Status

Research Site

Gdynia, , Poland

Site Status

Research Site

Iława, , Poland

Site Status

Research Site

Kościerzyna, , Poland

Site Status

Research Site

Krakow, , Poland

Site Status

Research Site

Sopot, , Poland

Site Status

Research Site

Tczew, , Poland

Site Status

Research Site

Warsaw, , Poland

Site Status

Research Site

Angra Do Herosmo, , Portugal

Site Status

Research Site

Braga, , Portugal

Site Status

Research Site

Castelo Branco, , Portugal

Site Status

Research Site

Coimbra, , Portugal

Site Status

Research Site

Covilha, , Portugal

Site Status

Research Site

Lisbon, , Portugal

Site Status

Research Site

Setúbal, , Portugal

Site Status

Research Site

Vila Real, , Portugal

Site Status

Research Site

Brasov, Brașov County, Romania

Site Status

Research Site

Iași, Iaşi, Romania

Site Status

Research Site

Bucharest, , Romania

Site Status

Research Site

Satu Mare, , Romania

Site Status

Research Site

Tg. Mures, , Romania

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Banska Bysterica, , Slovakia

Site Status

Research Site

Bánovce nad Bebravou, , Slovakia

Site Status

Research Site

Brastislava, , Slovakia

Site Status

Research Site

Liptovský Mikuláš, , Slovakia

Site Status

Research Site

Martin, , Slovakia

Site Status

Research Site

Nitra, , Slovakia

Site Status

Research Site

Nové Mesto nad Váhom, , Slovakia

Site Status

Research Site

Piešťany, , Slovakia

Site Status

Research Site

Považská Bystrica, , Slovakia

Site Status

Research Site

Trnava, , Slovakia

Site Status

Research Site

Cape Town, , South Africa

Site Status

Research Site

Durban, , South Africa

Site Status

Research Site

Johannesburg, , South Africa

Site Status

Research Site

Seongnam-si, Kyeonggi-do, South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Bangkok, , Thailand

Site Status

Research Site

Chiang Mai, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hungary United States Argentina Australia Bulgaria Canada Czechia Finland Germany Indonesia Mexico Norway Philippines Poland Portugal Romania Russia Slovakia South Africa South Korea Thailand

References

Explore related publications, articles, or registry entries linked to this study.

Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, Lanas A, Agewall S, Naucler EC, Svedberg LE, Nagy P. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. J Cardiovasc Pharmacol. 2013 Mar;61(3):250-7. doi: 10.1097/FJC.0b013e31827cb626.

Reference Type DERIVED
PMID: 23188121 (View on PubMed)

Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Naucler E, Svedberg LE. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011 May;97(10):797-802. doi: 10.1136/hrt.2010.217547. Epub 2011 Mar 17.

Reference Type DERIVED
PMID: 21415072 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EudraCT No. 2006-005073-22

Identifier Type: -

Identifier Source: secondary_id

D961FC00003

Identifier Type: -

Identifier Source: org_study_id